Clinical trial
A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
NCT04799275 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- May 20, 2021
- Completion date
- March 1, 2027
- Enrollment
- 422 (estimated)
- Sites
- 176
Conditions
As the registry lists them; a condition with its own page is linked.
ann arbor stage iii diffuse large b-cell lymphoma, ann arbor stage iix (bulky) diffuse large b-cell lymphoma, ann arbor stage iv diffuse large b-cell lymphoma, diffuse large b-cell lymphoma activated b-cell type, diffuse large b-cell lymphoma associated with chronic inflammation, diffuse large b-cell lymphoma germinal center b-cell type, diffuse large b-cell lymphoma, not otherwise specified, ebv-positive diffuse large b-cell lymphoma, not otherwise specified, grade 3b follicular lymphoma, hhv8-positive diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, intravascular large b-cell lymphoma, lymphoplasmacytic lymphoma, nodular lymphocyte predominant b-cell lymphoma, primary cutaneous diffuse large b-cell lymphoma, leg type, t-cell/histiocyte-rich large b-cell lymphoma, transformed follicular lymphoma to diffuse large b-cell lymphoma, transformed marginal zone lymphoma to diffuse large b-cell lymphoma